Blueshift Asset Management’s Vaxcyte PCVX Stock Holding History

Blueshift Asset Management’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$229K	Buy	+3,934	New	+$214K	0.05%	462

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Blueshift Asset Management's PCVX Position: Q2 2026 in Review

Blueshift Asset Management opened a new position in Vaxcyte (PCVX) in Q2 2026: 3,934 shares worth $229K. The stake represents 0.05% of the portfolio and ranks #462 among its holdings.

331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

Blueshift Asset Management held 3,934 shares of Vaxcyte worth $229K as of Q2 2026.
Vaxcyte was a new Blueshift Asset Management position in Q2 2026.
Vaxcyte made up 0.05% of Blueshift Asset Management's portfolio in Q2 2026, its #462 holding.
331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Blueshift Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.